SEARCH

SEARCH BY CITATION

References

  • 1
    Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 2005; 12: 33345.
  • 2
    Dusheiko G, Antonakopoulos N. Treatment of hepatitis B. Gut 2008; 57: 10524.
  • 3
    Liaw Y-F. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002; 17: S3337.
  • 4
    Yuen MF, Kato T, Mizokami M, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39: 8505.
  • 5
    Benhamou Y, Dohin E, Lunel-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 3967.
  • 6
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 7
    Liaw YF. 2008 APASL guidelines for HBV management. Hepatol Int 2008; 2: 26383.
  • 8
    European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 22742.
  • 9
    Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. J Hepatol 2007; 46: 7568.
  • 10
    Moucari R, Mackiewic V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 11517.
  • 11
    Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 114150.
  • 12
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 93662.
  • 13
    Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 25465.
  • 14
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 268295.
  • 15
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 120617.
  • 16
    Piratvisuth T, Lau G, Chao Y-C, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis. Hepatol Int 2008; 2: 10110.
  • 17
    Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 1239.
  • 18
    Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterol 2008; 135: 45967.
  • 19
    Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699705.
  • 20
    Marcellin P, Bonino F, Lau GKK, et al. Sustained responses in patients with HBeAg-negative chronic hepatitis B 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 216979.
  • 21
    Marcellin P, Piratvisuth T, Brunetto M, et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a±lamivudine: results of 5-year post-treatment follow-up. J Hepatol 2009; 5 (Suppl. 1): S336.
  • 22
    Cooksley G, Lau GKK, Marcellin P, et al Response to peginterferon alfa-2a (40KD) (PEGASYS®) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B. Presented at the 16th APASL meeting, Manila, Philippines, 5–8 March 2006.
  • 23
    Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46: 38894.
  • 24
    Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Sem Liver Dis 2006; 26: 14252.
  • 25
    Marcellin P, Lau GK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28: 47785.
  • 26
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 174351.
  • 27
    Marcellin P, Chang TT, Lim SGL, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B. Hepatology 2008; 48: 7508.
  • 28
    Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 100110.
  • 29
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis. N Engl J Med 2006; 354: 101120.
  • 30
    Shouval D, Lai CL, Chang TT, Cheinquer H, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50: 28995.
  • 31
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 257688.
  • 32
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 244255.
  • 33
    Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 11728.
  • 34
    Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46: 10418.
  • 35
    Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008; 2: 16378.
  • 36
    Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 7382.
  • 37
    Chen JJ, Wang ZH, Ma SW, et al. Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment. Zhonghua Gan Zang Bing Za Zhi 2008; 16: 41620.
  • 38
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 152131.
  • 39
    Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 171422.
  • 40
    Yen YH, Lu SN, Chen CH, et al. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int 2007; 27: 134955.
  • 41
    Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008; 2: 3047.
  • 42
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 43
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 44
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 267381.
  • 45
    Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 52836.
  • 46
    Chan HL, Heathcote EJ018 Study Group. et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 74554.
  • 47
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 131541.
  • 48
    Zeuzem S, Gane E, Liaw Y-F, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 1120.
  • 49
    Hsu C-W, Chen Y-C, Liaw Y-F, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients. J Hepatol 2009; 50 (Suppl. 1): S331.
  • 50
    Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology 2008; 48: A146.
  • 51
    Snow-Lampart A, Chappell BJ, et al. Week 96 resistance surveillance for HBe Ag positive patients and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg qd. Hepatology 2008; 48: A977.
  • 52
    Heathcote E, Gane EJ, DeMan RA, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 2008; 48: A158.
  • 53
    Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 102). J Hepatol 2008; 48: S26.
  • 54
    Sasadeusz JJ, Locarnini SL, Macdonald G. Why do we not yet have combination chemotherapy for chronic hepatitis B? Med J Aust 2007; 186: 2046.
  • 55
    Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 24050.
  • 56
    Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: 72835.
  • 57
    Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared with lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis. Abstract 69. J Hepatol 2003; 38: 2526.
  • 58
    Fung J, Lai CL, Yuen JC, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007; 12: 416.
  • 59
    Hui CK, Zhang HY, Bowden S, et al. 96 weeks of combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48: 71420.
  • 60
    Yuki N, Nagaoka T, Nokui K, et al. Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection. J Gastroenterol 2008; 43: 45763.
  • 61
    Akman SA, Okcu SC, Halicioglu O, et al. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatri Int 2007; 49: 84852.
  • 62
    Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-α and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005; 100: 246371.
    Direct Link:
  • 63
    Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 5628.
  • 64
    Serfaty L, Thabut D, Zoulim F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001; 34: 5737.
  • 65
    Marcellin P, Lau GKK, Bonino F, et al. Sustained response to peginterferon alfa-2a (40KD) (Pegasys) in HBeAg-negative chronic hepatitis B. 1-year follow-up data from a large, randomised multinational study. J Hepatol 2005; 42: 1856.
  • 66
    Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102: 96104.
    Direct Link:
  • 67
    Rudin D, Shah SM, Kiss A, Wetz RV, Sotille VM. Interferon and lamivudine vs interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 2007; 27: 118593.
  • 68
    Colonno RJ, Rose RE, Pokornowski K, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007; 46: S294.
  • 69
    Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol 2005; 43: 9203.
  • 70
    Delaney WE IV Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother 2007; 59: 82732.
  • 71
    Qi X, Xiong S, Yang H, Miller M, Delaney WE IV In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 35562.
  • 72
    Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 73
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 74
    Buti M, Elefsiniotis I, Jardi R, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007; 47: 36672.
  • 75
    Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 30713.
  • 76
    Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 138591.
  • 77
    Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 148895.
  • 78
    Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 28390.
  • 79
    Van Der Poorten D, Prakoso E, Khoo TL, et al. Combination adefovir–lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol 2007; 22: 15005.
  • 80
    Yatsuji H, Suzuki E, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48: 92331.
  • 81
    Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 144551.
  • 82
    Larrat S, Hilleret MN, Germi R, et al. Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs. Comp Hepatol 2008; 7: 3.
  • 83
    Akyildiz M, Gunsar F, Ersoz G, et al. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci 2007; 52: 34447.
  • 84
    Gaia S, Barbon V, Smedile A, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008; 48: 5407.
  • 85
    Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25: 8918.
  • 86
    Hosaka T, Suzuki F, Suzuki Y, et al. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007; 42: 36874.
  • 87
    Jang JW, Kim MS, Lee SY, et al. Pre- and post-treatment predictors of the early achievement of HBeAg loss in lamivudine-resistant patients receiving adefovir therapy. J Gastroenterol Hepatol 2007; 22: 10927.
  • 88
    Lee YS, Chung YH, Kim JA, et al. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Liver Int 2009; 29: 5526.
  • 89
    Hézode C, Chevaliez S, Bouvier-Alias M, et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol 2007; 46: 7916.
  • 90
    Liaw YF. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology 2007; 45: 2668.
  • 91
    Colonno RJ, Rose RE, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006; 44: 229A.
  • 92
    Nagasaki F, Niitsuma H, Ueno Y, et al. The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J Exp Med 2007; 213: 1816.
  • 93
    Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198209.
  • 94
    Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 203949.
  • 95
    Tenney DJ, Rose RE, Baldick CJ, et al. Two–year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 90211.
  • 96
    Choe WH, Kwon SY, Kim BK, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008; 28: 814820.
  • 97
    Manns, et al. Safety and efficacy of 96 weeks of tenofovir disoproxil fumarate therapy in lamivudine experienced patients. J Hepatol 2009; 50: S3356.
  • 98
    Marcellin P, Lau GK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28: 47785.
  • 99
    Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 108492.
  • 100
    Brunetto MR, Moriconi F, Cavallone D, et al. Reduction in serum HBsAg level in patients with chronic hepatitis B infected with genotype D induced by (pegylated)interferon alfa-2a alone or in combination with nucleos(t)ide analogs: a long-term single centre cohort study. Hepatology 2007; 46: 679A.
  • 101
    Moucari R, Mackiewicz V, Lada O, et al. HBsAg seroconversion: different kinetics of serum HBsAg level decrease in inactive carriers and chronic hepatitis B patients treated with interferon. Hepatology 2007; 46: 680A.
  • 102
    Vassiliadis T, Patsiaoura K, Tziomalos K, et al. Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12: 241722.
  • 103
    Marcellin P, Boyer N, Piratvisuth T, et al. Efficacy and safety of peginterferon alpha-2a (40kD) (Pegasys) in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues – the PEGALAM cohort. J Hepatology 2006; 44: S187.
  • 104
    Piratvisuth T, Boyer N, Tanwandee T, et al. Efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS®) in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues – the PEGaLAM cohort. Abstract presented at the 16th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, 2006.
  • 105
    Xu D–Z, Xie Y, Wei L, et al. Efficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: S266.
  • 106
    Shi XF, Guo SH, Liu Q, Wang RS, Ren H. Peginterferon alfa-2a for patients with HBeAg-positive CHB who failed prior lamivudine treatment. Hepatol Int 2007; 1: 090.
  • 107
    Hou J, Sun J, Xie Q, et al. Efficacy and safety of peginterferon alfa-2a versus adefovir dipivoxil (ADV) in treating lamivudine resistant HBeAg positive CHB: an interim analysis of a prospective randomized study. Hepatology 2008; 48: 745A.
  • 108
    Leemans WF, Flink HJ, Janssen HL, et al. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006; 44: 50711.
  • 109
    Chen CJ, Yang HI, Iloeje UH, et al. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49 (Suppl.): S7284.
  • 110
    Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 130919.